Spravato Treatment in New Jersey
FDA-approved esketamine (Spravato) for treatment-resistant depression — supervised care at our Maplewood clinic serving central & northern New Jersey.
At a glance
Spravato (esketamine) for treatment-resistant depression
Spravato is an FDA-approved nasal spray for adults with treatment-resistant depression who have not responded adequately to at least two antidepressant trials.
Skyview Health administers Spravato on-site in Maplewood, NJ under REMS protocol with required post-dose monitoring (typically about two hours).
Patients from Essex County and across northern and central New Jersey travel to our REMS-certified clinic. Call (973) 996-2078 to ask about screening and insurance verification.
Overview
What is Spravato?
Spravato (esketamine) is an FDA-approved nasal spray medication used in conjunction with an oral antidepressant for the treatment of treatment-resistant depression (TRD) in adults. It represents a significant advancement in mental health treatment, offering hope to those who have struggled to find relief through traditional antidepressant medications.
Treatment-resistant depression occurs when a person has tried at least two different antidepressant medications at adequate doses for an adequate duration without experiencing adequate improvement in their symptoms. Spravato is specifically approved for adults who have not responded to multiple antidepressant treatments.
Treatment
How Spravato Works
Spravato works differently than traditional antidepressants. It targets the glutamate system in the brain, specifically the N-methyl-D-aspartate (NMDA) receptors. This novel mechanism of action helps form new neural connections between brain cells, which can provide rapid relief for some patients.
Unlike traditional antidepressants that typically take weeks to show effects, Spravato can provide improvements sometimes seen within hours or days. This rapid response is particularly beneficial for individuals with severe depression who need immediate relief.
Spravato must be administered in a certified healthcare setting under the supervision of a healthcare provider, ensuring both safety and optimal treatment outcomes. Patients are monitored for at least 2 hours after each dose to observe any potential side effects.
Candidates
Who Can Benefit?
Spravato is specifically approved for adults with treatment-resistant depression (TRD), meaning you have tried at least two different antidepressant medications at adequate doses for an adequate duration without experiencing adequate improvement in your symptoms.
It is also approved for adults with major depressive disorder (MDD) who have suicidal thoughts or behaviors. If you've been struggling with depression despite trying multiple treatment approaches, Spravato may be an option worth discussing with your healthcare provider.
Schedule
Treatment Schedule
Induction Phase (Weeks 1-4)
During the first month, treatment is given twice weekly. Each session involves:
- Nasal spray administration under medical supervision
- 2-hour monitoring period after each dose
- Assessment of response and side effects
- Must be used in combination with an oral antidepressant
Maintenance Phase (Weeks 5-8)
During the next four weeks, treatment frequency is adjusted to once weekly:
- Continued weekly sessions as needed
- Ongoing monitoring and assessment
- Continued combination with oral antidepressant
- Evaluation of treatment response
Long-term Maintenance
After the initial 8 weeks, treatment frequency may be adjusted based on your response:
- Weekly or bi-weekly sessions as needed
- Continued monitoring and assessment
- Ongoing combination with oral antidepressant
- Regular follow-up care
Learn More
Learn More About Spravato
Watch this informative video to learn more about Spravato treatment and how it can help with treatment-resistant depression.
Safety
Important Information & Safety
Administration & Monitoring
- Spravato must be administered in a certified healthcare setting only
- Patients are monitored for at least 2 hours after each dose
- Treatment is given twice weekly during the first month (induction phase)
- Must be used in combination with an oral antidepressant
- Cannot be taken home - must be administered at the clinic
Side Effects & Precautions
- Common side effects include: dissociation, dizziness, nausea, sedation, and anxiety
- May cause temporary increase in blood pressure
- Do NOT drive or operate machinery on treatment days
- Arrange transportation home after each treatment session
- Not suitable for everyone - discuss with your provider
What to Expect During Treatment
During each treatment session, you will self-administer the nasal spray under medical supervision. After administration, you will be monitored for at least 2 hours. Some patients may experience temporary dissociation (feeling disconnected from reality), dizziness, or sedation. These effects are typically temporary and resolve within the monitoring period. It is essential to have someone drive you home after treatment, as you should not drive or operate heavy machinery on treatment days.
Insurance Coverage: Spravato is covered by most insurance plans for qualifying patients with treatment-resistant depression. Our team can help you verify your coverage and navigate the insurance process.
Central NJ
Spravato clinics in central New Jersey
Searching Spravato treatment New Jersey, Spravato treatment centers of New Jersey, or esketamine therapy NJ? Skyview Health at 2040 Millburn Ave Ste 206, Maplewood, NJ 07040, United States provides REMS-compliant Spravato for eligible adults with treatment-resistant depression (TRD).
Convenient to Newark, Jersey City, Elizabeth, and Essex County — call (973) 996-2078 to ask about screening. Guides: first Spravato session · Spravato for TRD.
FAQ
Spravato & TRD in New Jersey — FAQ
Where can I get Spravato treatment in New Jersey?
Skyview Health in Maplewood, NJ offers supervised Spravato (esketamine) nasal spray treatment for eligible adults with treatment-resistant depression, in a REMS-compliant clinical setting. Call (973) 996-2078 to ask about screening and scheduling.
Are there Spravato treatment centers of New Jersey?
Yes — Skyview Health is a Spravato treatment center in Maplewood, Essex County, serving patients from central and northern New Jersey. Spravato is given on-site with required post-dose monitoring under REMS protocol.
Are there Spravato clinics in central New Jersey?
Skyview Health serves central and northern New Jersey from Maplewood (Essex County), convenient to Newark, Jersey City, Elizabeth, Union, and Bergen County. Spravato is administered on-site with required post-dose monitoring.
What is treatment-resistant depression (TRD) treatment in NJ?
Treatment-resistant depression means major depression that has not improved after adequate trials of standard antidepressants. In New Jersey, eligible adults may consider Spravato plus an oral antidepressant under medical supervision — your Skyview provider can review your history and explain REMS requirements.
What is resistant depression treatment in New Jersey?
Resistant (treatment-resistant) depression care may include medication changes, therapy, and for eligible adults, Spravato (esketamine) nasal spray in a certified clinic. Skyview Health in Maplewood evaluates TRD history and discusses whether Spravato fits your situation.
What is esketamine therapy in New Jersey?
Esketamine (brand Spravato) is an FDA-approved nasal spray for adults with treatment-resistant depression, given in a certified clinic with monitoring. Skyview Health in Maplewood provides esketamine therapy when clinical criteria are met.
Is Spravato available near Newark or Essex County, NJ?
Skyview Health is located in Maplewood, Essex County — a short drive from Newark, South Orange, Millburn, and Irvington. We provide Spravato for eligible TRD patients with in-clinic monitoring.
Can patients from Bergen County (Oradell, Nutley) get Spravato at Skyview?
Many northern NJ patients travel to our Maplewood clinic for Spravato because treatment must occur in a REMS-certified setting with on-site monitoring. Call (973) 996-2078 to ask about scheduling and whether Spravato is appropriate for you.
Is Spravato covered by insurance in New Jersey?
Many plans cover Spravato for qualifying treatment-resistant depression when medical criteria are met. Skyview Health helps verify benefits and prior authorization requirements before starting treatment.
How long is each Spravato treatment session?
After the nasal spray is given under supervision, you remain in the clinic for monitoring — typically about two hours. You must arrange a ride home and avoid driving until the next day per REMS guidance.
Where can I find Spravato near me in New Jersey?
Skyview Health in Maplewood, NJ (2040 Millburn Ave Ste 206) is a REMS-compliant Spravato treatment center for eligible adults with treatment-resistant depression. Call (973) 996-2078 to ask about screening.
Is there an esketamine clinic near me for depression in Essex County?
Skyview Health administers Spravato (esketamine) nasal spray on-site in Maplewood, Essex County, with required post-dose monitoring. Many northern and central NJ patients travel here for certified in-clinic treatment.
Where can I get depression treatment near me if medications failed?
If standard antidepressants have not helped, eligible adults may discuss Spravato plus an oral antidepressant at Skyview Health in Maplewood. Your provider reviews TRD history and REMS requirements — call (973) 996-2078.
Ready to Learn More About Spravato?
If you've been struggling with treatment-resistant depression, Spravato may be an option for you. Contact us to schedule a consultation and see if Spravato treatment is right for you.
Ready to take the next step?
Schedule a visit in Maplewood or by telehealth. Our team is here to help you feel better and move forward with confidence.